If you have been reading about deamidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-11. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | Lyophilised solid form |
| Solubility | pH dependent; low near pI | Minimum close to pH 5.4 |
| Storage temperature | -20 C solid; 2-8 C solution | Protect from light |
| Isoelectric point | approx. pH 5.4 | Controls solubility minimum |
| Common analytical method | RP-HPLC with mass detection | Purity and identity checks |
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
== Epidemiology == In the United States, 1–8% of cancer patients are diagnosed with leptomeningeal disease, with approximately 110,000 cases per year. The exact incidence of leptomeningeal disease is difficult to determine, since gross examination at autopsy may overlook signs of leptomeningeal disease, and microscopic pathological inspection may be normal if the seeding is multifocal or if an unaffected area of the central nervous system (CNS) is examined.
== Anti–money laundering measures by region == Many jurisdictions adopt a list of specific predicate crimes for money laundering prosecutions, while others criminalize the proceeds of any serious crimes.
Medea resolves to kill her own children as well, not because the children have done anything wrong, but because she feels it is the best way to hurt Jason. She calls for Jason once more and, in an elaborate ruse, apologizes to him for overreacting to his decision to marry Glauce. When Jason appears fully convinced that she regrets her actions, Medea begins to cry in mourning of the exile. She convinces Jason to allow their two sons to give gifts to Glauce in hopes that Creon will lift the exile against the children. Eventually Jason agrees.
The PC version received "mixed or average reviews" according to the review aggregation website Metacritic. In a review for IGN, critic Tal Blevins noted that Blue Shift's gameplay "is pretty much what we've come to expect out of Half-Life" by blending action and puzzle solving, stating that the latter "were all logical and well done, although some of the jumping puzzles were frustrating". Though IGN praised the game for maintaining the "epic" feel of the original, Blevins was critical of the relatively short length of the game. GameSpot reviewer Greg Kasavin agreed with many of IGN's criticisms, stating that "it's not that the game is easy so much that it's extremely short" and that Blue Shift "doesn't amount to much on its own terms". In addition, Kasavin described the graphical enhancements brought about by the High Definition pack as "helpful", but noted that "they still don't make Half-Life look like a new game—nor are many of the changes themselves very noticeable". Other reviews echoed complaints about the similarity of Blue Shift to previous games. GameSpy reviewer Jamie Madigan stated that "what really pulls the game down is the 'more of the same' factor". Although writing that the game "feels like just a few more levels for the original game", he noted that this is what Blue Shift was designed to be, given its origins as an add-on for a Dreamcast version of Half-Life. Madigan described the single-player campaign as "decent" and commented that the new graphics made the game "worthy of consideration".
Sources: en.wikipedia.org
Finally, on June 15, 1977, the general election took place without any incident and with a very high turnout, close to 80% of the census. The victory went to Unión de Centro Democrático, a coalition of moderate parties and "independents" led by Prime Minister Adolfo Suárez, although it failed to achieve an absolute majority in the Congress of Deputies ─ it obtained 34% of the votes and 165 seats: it was 11 seats short of an absolute majority. The second winner was the PSOE, which became the hegemonic party of the left, obtaining 29.3% of the votes and 118 deputies, ousting by a wide margin the PCE, which obtained 9.4% of the votes and remained with 20 deputies, even though it was the party that had borne the greatest weight in the anti-Francoist struggle. The Partido Socialista Popular of Enrique Tierno Galván was also ousted, obtaining only six deputies and 4% of the votes. The other big loser of the elections, together with the PCE, was the neofranquist Alianza Popular of Manuel Fraga who only obtained 8.3% of the votes and 16 deputies ─ 13 of whom had been ministers under Franco. But the biggest setback was suffered by the Christian democracy of Joaquín Ruiz-Giménez and José María Gil Robles, the leader of the CEDA during the Second Republic, who did not obtain any deputies. On the other hand, neither the extreme right nor the extreme left achieved parliamentary representation.
== Laboratory == biochemistry Arterial blood gas (ABG) Complete blood count (CBC) Comprehensive metabolic panel (CMP) (including CHEM-7) coagulation tests C-reactive protein Erythrocyte sedimentation rate (ESR) FibroTest urea breath test urinalysis Agostini's reaction cytogenetics and Molecular Genetics Genetic testing immunology autoantibodies microbiology blood culture mantoux test sputum culture stool culture urine culture Where available ICD-11, where not ICD-10 codes are listed. See also: https://en.m.wikipedia.org/wiki/Category:Blood_tests and Blood test,
== External links == Peltola; et al. (2004). "News on cereulide, the emetic toxin of Bacillus Cereus". Appl Env Microbiol. 70 (8): 4996–5004.{{cite journal}}: CS1 maint: deprecated archival service (link) S. Pitchayawasin; M. Isobe; M. Kuse; T. Franz; N. Agata; M. Ohta (May 19, 2004). "Molecular diversity of cereulide" (PDF). International Journal of Mass Spectrometry. 235: 123–129. ISSN 1387-3806. Archived from the original (PDF) on March 13, 2005.
Sources: en.wikipedia.org
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.
Mass spectrometry, usually electrospray ionisation coupled to liquid chromatography, gives an observed mass for comparison with the theoretical value. Peptide mapping after digestion provides complementary sequence-level confirmation.
Short exposure during weighing and handling is generally tolerated, but prolonged storage above refrigerated conditions raises the risk of deamidation, oxidation, and aggregation. The rate depends on pH, buffer composition, and concentration.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.